Literature DB >> 19007331

Immune therapy for cancer.

Michael Dougan1, Glenn Dranoff.   

Abstract

Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19007331     DOI: 10.1146/annurev.immunol.021908.132544

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  231 in total

Review 1.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

Review 2.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

3.  Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.

Authors:  Jamie L Harden; Tao Gu; Mehmet O Kilinc; Rachael B Rowswell-Turner; Lauren P Virtuoso; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 4.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 5.  Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.

Authors:  Hongmei Xu; Xuetao Cao
Journal:  Front Med       Date:  2011-12       Impact factor: 4.592

Review 6.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 7.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 8.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

9.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

10.  Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

Authors:  Juan Fu; Ian-James Malm; Deepak K Kadayakkara; Hy Levitsky; Drew Pardoll; Young J Kim
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.